Zhu Zhaowei, Fang Zhenfei, Hu Xinqun, Zhou Shenghua
The Second Xiangya Hospital, Central South University, Huan Province, CN.
Department of Cardiology, Second Xiangya Hospital, Central South University, Huan Province, CN.
Rev Bras Cir Cardiovasc. 2015 Jul-Sep;30(3):380-5. doi: 10.5935/1678-9741.20150033.
Pulmonary hypertension is a devastating and refractory disease and there is no cure for this disease. Recently, microRNAs and mesenchymal stem cells emerged as novel methods to treat pulmonary hypertension. More than 20 kinds of microRNAs may participate in the process of pulmonary hypertension. It seems microRNAs or mesenchymal stem cells can ameliorate some symptoms of pulmonary hypertension in animals and even improve heart and lung function during pulmonary hypertension. Nevertheless, the relationship between mesenchymal stem cells, microRNAs and pulmonary hypertension is not clear. And the mechanisms underlying their function still need to be investigated. In this study we review the recent findings in mesenchymal stem cells - and microRNAs-based pulmonary hypertension treatment, focusing on the potential role of microRNAs regulated mesenchymal stem cells in pulmonary hypertension and the role of exosomes between mesenchymal stem cells and pulmonary hypertension.
肺动脉高压是一种严重且难治的疾病，目前尚无治愈方法。最近，微小RNA和间充质干细胞成为治疗肺动脉高压的新方法。20多种微小RNA可能参与肺动脉高压的发生过程。似乎微小RNA或间充质干细胞可以改善动物肺动脉高压的一些症状，甚至在肺动脉高压期间改善心肺功能。然而，间充质干细胞、微小RNA与肺动脉高压之间的关系尚不清楚。其功能的潜在机制仍需研究。在本研究中，我们综述了基于间充质干细胞和微小RNA治疗肺动脉高压的最新研究成果，重点关注微小RNA调控的间充质干细胞在肺动脉高压中的潜在作用以及外泌体在间充质干细胞与肺动脉高压之间的作用。
